EPKINLY FDA Approval: A Milestone in Diffuse Large B-Cell Lymphoma Treatment
The EPKINLY FDA approval marks a major breakthrough in the management of diffuse large B-cell lymphoma (DLBCL). Co-developed by AbbVie and Genmab, EPKINLY (epcoritamab-bysp) has become the first and only CD20xCD3 bispecific antibody approved for adult patients with relapsed or refractory DLBCL after at least two prior systemic therapies. This approval highlights a significant advancement in bispecific antibodies DLBCL treatment, offering new therapeutic possibilities for patients with limited options. Activate T-cells against cancer - Learn about CD20xCD3: https://www.delveinsight.com/blog/abbvie-genmab-epkinly-approval-for-dlbcl-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=akpr What Is EPKINLY and How It Works EPKINLY is a subcutaneous bispecific antibody that binds to CD20 on malignant B-cells and CD3 on T-cells. This mechanism harnesses the immune system to directly attack cancer cells, bypassing the need for traditional chemotherapy. As part of the EPKINLY b...